Beijing Hotgen Biotech Co Ltd (688068) — Capital Reinvestment Ratio

Latest as of September 2025: 4.82x

Beijing Hotgen Biotech Co Ltd (688068) has a Capital Reinvestment Ratio of 4.82x as of September 2025, meaning it reinvests 5% of its operating cash flow (CN¥3.05 Million) in capital expenditures (CN¥14.73 Million). See Beijing Hotgen Biotech Co Ltd (688068) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

4.82x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥3.05 Million
CNY

Capital Expenditures

CN¥14.73 Million
CNY

Data as of

Sep 2025
Most recent filing

Beijing Hotgen Biotech Co Ltd Capital Reinvestment Ratio (2016–2022)

This chart tracks Beijing Hotgen Biotech Co Ltd's Capital Reinvestment Ratio across 7 annual periods.

Annual Capital Reinvestment Ratio for Beijing Hotgen Biotech Co Ltd (2016–2022)

Year-by-year Capital Reinvestment Ratio for Beijing Hotgen Biotech Co Ltd from 2016 to 2022. For live market cap and broader valuation context, see market cap of Beijing Hotgen Biotech Co Ltd.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2022 0.58x CN¥978.75 Million CN¥565.21 Million ▲ +282.9%
2021 0.15x CN¥2.64 Billion CN¥398.86 Million ▼ -85.6%
2020 1.05x CN¥164.62 Million CN¥172.27 Million ▼ -77.1%
2019 4.57x CN¥19.37 Million CN¥88.48 Million ▲ +498.5%
2018 0.76x CN¥55.04 Million CN¥42.00 Million ▼ -74.6%
2017 3.01x CN¥22.95 Million CN¥69.05 Million ▲ +546.9%
2016 0.47x CN¥45.54 Million CN¥21.18 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow